{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:A6NK06",
      "entity_text" : "CAD",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:6022",
      "entity_text" : "ADP",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "Inhibition of ADP induced platelet aggregation with thienopyridines is a mainstay of CAD treatment, and it will be important to consider race in the pharmacogenetics of these anti-platelet therapies.",
  "reading_complete" : "2020-08-04T14:26:52Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T14:23:08Z",
  "trigger" : "induced",
  "evidence" : [ "ADP-induced platelet aggregation with thienopyridines is a mainstay of CAD" ],
  "pmc_id" : "4448541",
  "score" : 0
}